electroporation buffer containing doxorubicin dox (LC Laboratories)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

LC Laboratories electroporation buffer containing doxorubicin dox

CELVEC as a drug delivery vehicle. ( A ) Loading of <t>doxorubicin</t> (DOX) into CELVEC as a function of initial DOX concentration used. ( B ) Release of DOX from macrophages over 24 h when loading was performed passively (left) or supplemented with electroporation (right). Inset graphs depict DOX release over 6 h as determined using a one-phase association ordinary fit line. Dotted black line designated 50% release of payload. ( C ) Cellular viability of human MDA-231 triple negative breast cancer cells following treatment with free DOX and DOX-loaded CELVEC at low (325 nM) and high (975 nM) dosages. The data is plotted as the mean ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001.

Electroporation Buffer Containing Doxorubicin Dox, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/electroporation+buffer/electroporation+buffer+containing+doxorubicin+dox/pmc06957529-35-3-5
Average 90 stars, based on 1 article reviews

electroporation buffer containing doxorubicin dox - by Bioz Stars, 2026-11

90/100 stars

Images

1) Product Images from "Biomimetic cellular vectors for enhancing drug delivery to the lungs"

Article Title: Biomimetic cellular vectors for enhancing drug delivery to the lungs

Journal: Scientific Reports

doi: 10.1038/s41598-019-55909-x

CELVEC as a drug delivery vehicle. ( A ) Loading of doxorubicin (DOX) into CELVEC as a function of initial DOX concentration used. ( B ) Release of DOX from macrophages over 24 h when loading was performed passively (left) or supplemented with electroporation (right). Inset graphs depict DOX release over 6 h as determined using a one-phase association ordinary fit line. Dotted black line designated 50% release of payload. ( C ) Cellular viability of human MDA-231 triple negative breast cancer cells following treatment with free DOX and DOX-loaded CELVEC at low (325 nM) and high (975 nM) dosages. The data is plotted as the mean ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001.

Figure Legend Snippet: CELVEC as a drug delivery vehicle. ( A ) Loading of doxorubicin (DOX) into CELVEC as a function of initial DOX concentration used. ( B ) Release of DOX from macrophages over 24 h when loading was performed passively (left) or supplemented with electroporation (right). Inset graphs depict DOX release over 6 h as determined using a one-phase association ordinary fit line. Dotted black line designated 50% release of payload. ( C ) Cellular viability of human MDA-231 triple negative breast cancer cells following treatment with free DOX and DOX-loaded CELVEC at low (325 nM) and high (975 nM) dosages. The data is plotted as the mean ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001.

Techniques Used: Concentration Assay, Electroporation

Effect of DOX loading in CELVEC performance. ( A ) Flow cytometry dot plot depicting PS on CELVEC (blue) and DOX@CELVEC (green) surface 4 h post-generation. ( B ) Quantitative assessment of flow cytometry dot plot data exhibiting DOX and Annexin V positive cells using gates established in (A). ( C ) Cytotoxic evaluation of murine macrophage cells following electroporation (CELVEC, blue) and electroporation supplemented with DOX (DOX@CELVEC, green) to create DOX@CELVEC. Neutral red uptake was employed to evaluate cellular viability and proliferation over 72 h. Doxorubicin loading was performed at 20 mg/mL. Values normalized to untreated murine macrophages (CTRL). ( D ) Quantification of CELVEC adhered to TNF-α-activated HUVEC following 30 min of in vivo -like flow conditions of 0.1 dyn/cm 2 . ( E ) Representative fluorescent microscope images used for ( D,E ) depicting CELVEC adhesion following 30 min. of flow. Scale bar, 100 μm. The data is plotted as the mean ± SEM. ***p < 0.001.

Figure Legend Snippet: Effect of DOX loading in CELVEC performance. ( A ) Flow cytometry dot plot depicting PS on CELVEC (blue) and DOX@CELVEC (green) surface 4 h post-generation. ( B ) Quantitative assessment of flow cytometry dot plot data exhibiting DOX and Annexin V positive cells using gates established in (A). ( C ) Cytotoxic evaluation of murine macrophage cells following electroporation (CELVEC, blue) and electroporation supplemented with DOX (DOX@CELVEC, green) to create DOX@CELVEC. Neutral red uptake was employed to evaluate cellular viability and proliferation over 72 h. Doxorubicin loading was performed at 20 mg/mL. Values normalized to untreated murine macrophages (CTRL). ( D ) Quantification of CELVEC adhered to TNF-α-activated HUVEC following 30 min of in vivo -like flow conditions of 0.1 dyn/cm 2 . ( E ) Representative fluorescent microscope images used for ( D,E ) depicting CELVEC adhesion following 30 min. of flow. Scale bar, 100 μm. The data is plotted as the mean ± SEM. ***p < 0.001.

Techniques Used: Flow Cytometry, Electroporation, In Vivo, Microscopy